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Macrophages, which do not usually divide during in vitro cultivation, made 
DNA after virus-induced fusion with a  strain of mouse melanoma cells which 
does proliferate in vitro (1, 2). 
The  macrophage  heterokaryons  presented  several  advantages  as  a  model 
system to study the initiation of DNA synthesis: unfused macrophages made 
no DNA and the onset of DNA synthesis was rapid, synchronous,  and repro- 
ducible so that it was possible to  study the requirements  for DNA  synthesis 
in  the  macrophage  nucleus.  The  induction  of  macrophage  DNA  synthesis 
depended  upon  heterokaryon  RNA  synthesis  contributed  entirely  by  the 
melanoma nucleus. 
In the present studies we examine the role of heterokaryon protein synthesis 
in activating macrophage DNA synthesis and again evaluated the contribution 
of  each  parent  cell.  We  also  studied  the  effect  on  DNA  synthesis  of  fusing 
melanoma cells at different stages of their cell cycle. 
Materials and Methods 
Cell Culture and  Virus-Induced Fusion.--The methods of cell culture and virus-induced 
fusion have been described previously (1). 2 X  105 mouse peritoneal macrophages were culti- 
vated on 12-ram cover glasses for 1-2 days. Exponentially  growing or synchronized melanoma 
cells were then added to the macrophage monolayer. 500 hemagglutinating units of ultraviolet 
irradiated Sendai virus were used to initiate fusion 1 hr later. 
Inhibitors.--Cycloheximide  and streptovitacin A were obtained from Dr. S. Silverstein of 
The Rockefeller University. Concentrated stock solutions were stored at --20°C and thawed 
before use. Aetinomycin was used as before (2). 
In order to study the effects of inhibitors on unfused cells, we measured the incorporation 
of  leucine-3H,  uridine-3H,  and  thymidine-3H  into  trichloroacetic acid  (TCA)-insoluble I 
product. In some experiments the cumulative incorporation of precursor was measured  during 
drug treatment as well as subsequently;  in others, only after washing out the drug. 
* This work was partially supported by Grant AI 07012 from  the National Institutes of 
Health. 
1  Abbreviations used in this paper: PCA, perchloric acid; TCA, trichloroacetic acid. 
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Inhibitors were also used to treat cells either selectively, before fusion,  or after fusion (2). 
The preparations were then washed three times with medium 199 (Microbiological Associates, 
Inc., Bethesda,  Md.)  to remove excess inhibitor. DNA,  tZNA,  and  protein  synthesis were 
measured in fused preparations by radioautography (1). 
Melanoma Cdls.--Synchronized  melanoma cells were obtained by shaking cells in mitosis 
from monolayer cultures. Melanoma cells, growing exponentially in Falcon T-75 flasks (Falcon 
Plastics, Los Angeles,  Cafif.),  were rinsed twice with a solution of phosphate-buffered saline 
which lacked divalent cations. These washes were discarded. Flasks were next shaken vigor- 
ously and dislodged cells collected and spun dmvn. These cells were gently resuspended in a 
small volume of culture medium 199 with 20% newborn calf serum and 5 )< 103-1 X  10  ~ cells 
added to 1-day old macrophage monolayers. Two T-75 flasks  (Falcon) fielded enough cells 
for 20-40 cover slips. After 1-2 hr incubation to permit attachment of the melanoma cells, the 
preparations were gently washed and incubated further. The cocultivated cells were fused by 
the usual method at different times after replating the melanoma cells. Many doublets, cells 
in telophase, were seen soon after replating the melanoma cells. The degree of cell synchrony 
was estimated by radioautography after serial 2-hr pulses with thymidine-3H. 
Inhibitors were also used in experiments with synchronized melanoma cells, in which case 
the inhibitor was added at different times after replating the melanoma cells, i.e., at different 
stages of the melanoma cell cycle. The inhibitor was either added at the time of fusion or 2 hr 
afterwards and treatment was then maintained continuously until the end of the experiment. 
Characterization of the Perchloric Acid  (PCA)-Soluble  Pool  after Incubation  in  Thymi- 
dlne-3II.--Macrophages  or melanoma cells were cultivated in 60-mm  Falcon plastic tissue 
culture dishes for 1 day. The cells were washed twice with warm phosphate-buffered saline 
and exposed  for 4 hr to 4/zCi/ml thymidine-3H in medium 199 +  10% newborn calf serum. 
After two washes in ice-cold saline, the cells were scraped in saline and mixed with 5% ice-cold 
perchioric acid. The PCA-soluble fraction was washed twice with 1:3 ethanol:ether and then 
brought  to pH 5 with 6 ~  KOH. The K  perchlorate was spun down and  the supernatant 
fraction concentrated in vacuo. The PCA-soluble constituents were separated by high voltage 
paper electrophoresis at pH 3.5, eluted from the paper, and their radioactivity measured in a 
scintillation counter. 
RESULTS 
The kinetics of activation of macrophage DNA synthesis have been described 
previously  (2).  A  wave of  DNA  synthesis  started  in  the  previously  dormant 
macrophage  nuclei  2-3  hr  after  fusion  with  exponentially  growing  melanoma 
cells.  50-80%  of  the  macrophage  nuclei  in  heterokaryons  made  DNA  within 
6-8  hr  of fusion.  The  role  of  protein  synthesis  in  this  activation  process  was 
studied with  the aid of inhibitors  of protein  synthesis. 
Protein  Synthesis  and  the  Activation  of Macrophage  DNA  Synthesis.--The 
effect of cycloheximide on macromolecular  synthesis  in unfused  cells was  first 
determined  (Table I). 91-97 %  of protein  synthesis  could  be inhibited  in both 
melanoma  cells and  macrophages  during  a  3  hr  period  of treatment  with  1-5 
#g/ml  cycloheximide. This effect was reversible for both cell types.  Melanoma 
cell DNA  synthesis  was  depressed  54-73 %  by  such  cycloheximide treatment 
and RNA  synthesis inhibited to a  maximum value of 45 %. 
Cycloheximide was  next used  to inhibit protein  synthesis  in  heterokaryons. 
Fig. 1 a  illustrates the effect of 3 hr treatment with different doses of cyclohexi- 
mide  on  the  activation  of  macrophage  DNA  synthesis  in  heterokaryons.  In TABLE  I 
The Effect of Cycloheximide  on Protein,  RNA, and DNA Synthesis in  Unfused  Cells* 
Tracer 
Time after 
Dose  start of 
eycloheximide cycloheximide 
treatment 
Incorporation  (cpm,h*g  protein)  Per cent inhibition 
MEL:~  MAC$  M.EL  MAC 
~g/ml  kr 
Leu~ne-3I-I  0  3  160  84 
4  215  128 
6  320  180 
0.1  3  40  38  75  55 
4  110  80  49  38 
6  205  160  36  11 
1.0  3  9  78  94  91 
4  66  34  63  73 
6  155  68  52  62 
5.0  3  6  2,8  96  97 
4  50  34  52  73 
6  135  68  60  62 
Uridine-3H  0  3  230  310 
5  430  420 
7  608  600 
0.1  3  160  387  30  --25 
5  355  400  17  5 
7  600  500  I  17 
1.0  3  137  226  40  27 
5  301  255  30  39 
7  580  390  5  35 
5.0  3  135  220  41  29 
5  250  230  42  45 
7  432  390  30  35 
Thymidine-SH  0  3  170 
5  250 
7  361 
0.1  3  95  44 
5  142  43 
7  206  43 
1.0  3  79  54 
5  66  73 
7  125  65 
5.0  3  53  69 
5  66  73 
7  125  65 
* Cells were treated with cycloheximide for 3 hr in the presence of radioactive precursor, 
washed three times, and then incubated in fresh precursor without drug. 
:~ MEL, melanoma cell; MAC, macrophage. 
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contrast with the rapid and efficient stimulation of DNA synthesis in untreated 
heterokaryons, cycloheximide treatment diminished  and delayed this  process 
in a dose related fashion. Cycloheximide treatment did not diminish the number 
of melanoma nuclei making DNA in this experiment since 60-72 %  of nuclei 
were labeled with  thymidine in  both  the  treated  and  control groups.  Some 
macrophage nuclei which made no DNA as a result of cycloheximide treatment 
were nevertheless enlarged. 
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FIG. 1.  The activation of macrophage DNA synthesis in heterokaryons after the inhibition 
of protein synthesis. (a) Cycloheximide treatment after fusion.  (b) Streptovitacin treatment 
before fusion. 
To find out which  cell made  the  proteins required for macrophage DNA 
synthesis, each cell was treated, before fusion, with streptovitacin A, an irre- 
versible inhibitor of protein synthesis. Preliminary experiments to determine 
the effect of streptovitacin A on unfused cells are shown in Table II. Treatment 
with 2 ~g/ml for 1 hr suppressed 79-86% of protein synthesis in both macro- 
phages and melanoma cells.  This effect was not reversed during a subsequent 
4  hr  period  of incubation  without  inhibitor.  Maximal  inhibition  of protein 
synthesis was associated with 74 % inhibition of DNA and 45 %  inhibition of 
RNA synthesis. 
The effect of streptovitacin pretreatment before cell fusion is shown in Fig. 
1 b. Macrophage DNA synthesis was unaffected by pretreating macrophages 
with 2 ~g/ml streptovitacin, but melanoma cell pretreatment at 2 ~g/ml clearly TABLE  II 
The Effect of Streptovitacin  A  on Protein,  RNA, and DNA Synthesis  in  Unfused 
Cdls* 
Tracer 
Incorporation  Dose  Time after  (cpm/~g  protein)  Per cent inhibition 
streptovitacin washing  out 
drug  MEL  MAC  MEL  MAC 
Leucine-3H 
#g/ml  hr 
0  2  108  180 
4  222  300 
0.1  2  76  84  30  53 
4  156  169  30  43 
0.5  2  44  N.D.  59  N.D. 
4  80  N.D.  64  N.D. 
1.0  2  26  26  76  86 
4  66  64  70  79 
2.0  2  18  N.D.  84  N.D. 
4  46  N.D.  79  N.D. 
5.0  2  16  17  85  90 
4  42  40  81  87 
10.0  2  12  N.D.  89  N.D. 
4  38  N.D.  83  N.D. 
Uridine-3H  0  2  220  194 
4  444  400 
0.1  2  212  294  4  --50 
4  380  478  14  --20 
0.5  2  182  N.D.  17  N.D. 
4  300  N.D.  32  N.D. 
2.0  /  2  124  202  44  --1 
5.0!  4  248  248  45  38 
10.~ 
Thymidine-3H  0  4  170 
7  320 
0.1  4  175  8 
7  290  9 
1.0  4  70  63 
7  110  66 
2.o\  4  so  74 
10.0~  7  100  69 
* Cells were treated with streptovitacin for 1 hr, washed 3 times, and incubated in radio- 
active precursor without inhibitor. 
:~ N.D., not done. 
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TABLE  III 
Leucine Labding after Streptovitacin  Pretreatment* 
1:1 Heterokaryons  Unfused macrophages 
Pretreatment  Melanoma nucleus  Macrophage  Nucleus  Cytoplasm 
nucleus  Cytoplasm 
Mean  sE  Mean  SE  Mean  SE  Mean  SE 
Control  84.4  9.9  31.5  3.3  >200  4.5  0.76  15.3  2.0 
Macrophages  96.9  3.3  34.6  2.2  >200  1.3  0.56  5.0  1.0 
Melanoma cells  33.0  3.8  12.3  1.9  75.1  5.5  0.87  19.6  2.2 
* Melanoma cells  or macrophages were treated with 2 #g/ml streptovitacin A  for 1 hr 
before fusion. Preparations were exposed to L-leucineUH, 10 #Ci/ml,  1-2  hr after fusion. 
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FIG. 2.  DNA synthesis in heterokaryons after fusion of macrophages with synchronized 
melanoma cells. 
depressed the activation of macrophage DNA synthesis. A  dose related effect 
on  macrophage DNA  synthesis  could  be  shown  when  melanoma  cells  were 
pretreated with 0.5-2  /zg/ml, whereas even 20/zg/ml pretreatment of macro- 
phages  had  no  effect  on  subsequent  activation.  52-72%  of  melanoma  cell 
nuclei were labeled with thymidine in all these experiments. SAIMON  GORDON  AND  ZANVIL  COHN  941 
Cells were also incubated with leucine-3H after streptovitacin pretreatment 
to measure protein synthesis in fused preparations (Table III). In the untreated 
control the macrophage nuclei inside heterokaryons were more heavily labeled 
than  those in unfused  cells  (31.5  vs. 4.5  grains/nucleus).  After streptovitacin 
pretreatment of macrophages, the heterokaryon grain counts were undiminished 
in all  cell compartments  whereas  cytoplasm and both  nuclei  showed reduced 
labeling after melanoma cell pretreatment.  Macrophage DNA synthesis could 
therefore be depressed  by selective  inhibition  of melanoma protein  synthesis. 
TABLE IV 
DNA  Synthesis in Macrophage-Mdanoma  Cell Heterokaryons after Inhibiting  RNA  and Pro- 
rein Synthesis at Different Times during the Melanoma Cell Cycle 
Inhibitor  Time of fusion*  Start of inhibitor 
treatmentt 
Maximum 07o thymidine labeling 
in heterokaryon§ 
Macrophage nuclei  Melanoma nuclei 
hr  hr 
9 (or earlier)  --  86  96 
15  --  60  70 
Aetinomycin  2  4  0  6 
(2 #g/ml)  5  7  8  20 
7  9  40  70 
11  13  70  70 
15  15  20  73 
Cycloheximide  4  6  2  8 
(5~g/ml)  7  9  44  84 
10  12  80  90 
15  15  37  87 
Streptovitacin  A  15  15  33  73 
(2/zg/ml) 
* Mitotic melanoma cells replated on macrophage monolayers at time zero. 
:~ Inhibitors were present continuously until the end of the experiment. 
§ 2-hr thymidine pulses until 21 hr after replating melanoma cells. 
Fusion  Studies  with  Synchronized  Melanoma  Cells--When  melanoma  cells 
in mitosis were replated  on macrophage monolayers, they entered  S in a  syn- 
chronous fashion 11 hr later and 98 % of melanoma cells labeled with thymidine 
4-6 hr thereafter  (Fig.  2). The exit from S into G2 was less synchronous and 
the peak of mitosis occurred 23 hr after replating. The cell cycle after  replating 
was  thus  considerably  longer  than  the  12  hr  doubling  time  observed  during 
exponential growth of melanoma cells. 
Fig. 2 also shows DNA synthesis in heterokaryons after fusing macrophages 
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cycle. The onset of melanoma cell DNA synthesis was not affected by exposure 
to  Sendal virus or by fusion with  a  macrophage.  When  the  melanoma  cells 
were in G1 at the time of fusion (Fig. 2 a and b), macrophage DNA synthesis 
was  delayed until after the onset of melanoma cell S.  When fusion occurred 
late in melanoma G1 (Fig. 2 c) or in mid-S  (Fig. 2 d), macrophage DNA syn- 
thesis showed the basic 3 hr lag in initiation  and then proceeded rapidly to 
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FIG. 3. ".['he PCA-so]ub]e products of thymidine-3H  in umfusod ceils. 
involve 80-85 % of the macrophage nuclei. As the melanoma cells reached the 
end of S  (Fig. 2 e), fewer macrophage nuclei entered S after fusion, until the 
start of the next melanoma cell cycle (Fig. 2 f). 
These  experiments  showed  clearly  that  macrophage  DNA  synthesis  was 
under the control of the melanoma cell cycle. The macrophage nucleus, how- 
ever,  still  lagged  in  its  response  even  after  fusion  with  melanoma  cells  in 
mid-S. 
Protein  and  RNA  synthesis were next inhibited  at  different times during 
the melanoma cell cycle (Table IV). DNA synthesis was prevented in both the SAIMON  GORDON  AND  ZANVIL  COHN  943 
melanoma and macrophage nuclei if actinomycin or cycloheximide treatment 
was  started in mid-Ga  (4-7  hr).  When inhibitor treatment was delayed till 
late G1  (9 hr), more melanoma than macrophage nuclei initiated DNA syn- 
thesis. Both nuclei achieved maximum initiation of DNA synthesis if macro- 
phages were fused with melanoma cells in S and inhibition delayed for 2 hr. 
However, when the heterokaryons were immediately treated with inhibitors of 
RNA or protein synthesis (fusion at 15 hr), the number of labeled macrophage 
nuclei was reduced selectively. 
The PCA-Soluble  Products of Thymidine-3tI  in  Unfused  Cells.--It was ap- 
parent that macrophage DNA synthesis depended, in the main, on precursor 
products made by the melanoma cell.  Could unfused macrophages by them- 
selves  convert thymidine-3H to thymidine triphosphate for incorporation into 
DNA? Macrophages and melanoma cells showed quite different profiles of their 
perchloric acid-soluble thymidine products  (Fig. 3).  Thymidine taken up by 
the macrophage remained unphosphorylated, whereas it was recovered mainly 
as  thymidine  triphosphate  from  the  melanoma  cells.  Macrophages  and 
melanoma cells therefore differ strikingly in thymidine kinase activity. 
DISCUSSION 
The  experiments  with  cycloheximide showed  that  protein  synthesis  was 
required for the macrophage nucleus to enter S; the studies with streptovitacin 
A  suggested  that  these  proteins  came from  the  melanoma cell.  These  two 
compounds are closely related in structure and mode of action, although the 
detailed mechanism of inhibition has not been determined (3, 4). In  addition 
streptovitacin A becomes irreversibly bound within cells. 
Although macrophage  and melanoma cell  cytoplasm mix intimately after 
fusion, macrophage pretreatment with streptovitacin did not inhibit hetero- 
karyon protein or DNA synthesis. Its selective action argues against free dif- 
fusion of this drug within the fused cell.  Emetine hydrochloride, a  different 
irreversible inhibitor of protein synthesis (5), did abolish heterokaryon protein 
synthesis after macrophage pretreatment  (unpublished observations). 
The studies with synchronized melanoma cells  showed, in agreement with 
findings in  other heterokaryon systems  (6),  that  the  S phase  predominates 
over  Go.  DNA  synthesis initiation in both  the  melanoma and macrophage 
nuclei requires RNA and protein synthesis. The novel aspects of the present 
study include the characteristic lag in macrophage response and the continued 
dependence  on  RNA  and  protein  synthesis at  melanoma mid-S  to  initiate 
macrophage DNA synthesis. 
Macrophages and melanoma cells  differ in  thymidine kinase activity and 
thymidine triphosphate content after incubation in thymidine-3H. This distinc- 
tion is typical of resting and proliferating cells, but is not considered to be of 
primary importance in regulating DNA synthesis (7, 8). 
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own  cell  cycle,  provides  RNA,  proteins,  and  precursors  which  act  upon  a 
relatively inert macrophage nucleus to induce DNA synthesis. It is likely that 
proteins,  ions, and DNA precursor enzymes are transported  into the macro- 
phage nucleus during the early phase of swelling. The distribution of leucine-aH 
label  in  control  and  streptovitacin pretreated  cells  is  compatible  with  this 
hypothesis and  also  argues  against drug-insensitive protein  synthesis within 
the macrophage nucleus itself (9,  10).  The transport of cytoplasmic proteins 
into heterokaryon nuclei would account, in part, for their increase in dry mass 
during activation (11). Cytoplasmic factors, including proteins, are also neces- 
sary to support DNA synthesis in isolated nuclei (12,  13) and in frog somatic 
cell nuclei which have been transplanted into egg cytoplasm (14, 15). Labeled 
proteins previously synthesized by melanoma cells can be found in the macro- 
phage nuclei of heterokaryons prepared  in the presence  of protein  synthesis 
inhibitors  (unpublished  radioautographic  observations).  Future  progress  in 
characterizing the melanoma proteins which  initiate macrophage DNA  syn- 
thesis will require their characterization from macrophage nuclei isolated from 
heterokaryons. 
However, the macrophage nucleus cannot be completely passive during the 
activation process.  In the absence of a requirement for new macrophage RNA 
and protein synthesis, the lag in response of the macrophage nucleus could be 
because of physical changes which prepare the DNA template for replication 
(16).  The nature and duration of these changes may be related to the hetero- 
chromatin content of the macrophage nucleus (2, 8). 
This macrophage heterokaryon system therefore makes it possible to separate 
the role of template and inducing signals in bringing about DNA synthesis in 
Go cells. 
SUMMARY 
Dormant macrophage nuclei initiate DNA synthesis 2-3  hr after fusion of 
macrophages with exponentially growing melanoma cells. Cycloheximide treat- 
ment  (1-5  ~g/ml)  of heterokaryons during the preceding lag period inhibits 
the initiation of macrophage DNA synthesis, in a reversible fashion. Each type 
of cell was also treated with streptovitacin A, an irreversible inhibitor of protein 
synthesis.  Pretreatment  of  the  melanoma  cells  (0.5  2  #g/ml),  1  hr  before 
fusion, inhibited the induction of macrophage DNA synthesis in heterokaryons, 
whereas pretreatment of macrophages (1-20 ~g/ml) had no effect. Melanoma 
cell pretreatment reduced the incorporation of leneine-aH  into the cytoplasm 
and nuclei of heterokaryons, whereas macrophage pretreatment had no effect. 
These experiments suggested that melanoma proteins played an important role 
in the initiation of macrophage DNA synthesis. 
The relationship between  the melanoma cell  cycle and macrophage DNA 
synthesis was studied with synchronous melanoma cells. If the melanoma ceils SAIMON  GORDON  AND  ZANVIL  COHN  945 
were in S phase at the time of fusion, macrophage DNA synthesis occurred 2 
hr  later.  However,  the  fusion  of melanoma cells  in  G1  delayed  macrophage 
DNA  synthesis until  the melanoma nuclei  had  entered  S.  Experiments with 
actinomycin  and  cycloheximide showed  that  RNA  and  protein,  essential  to 
achieve DNA synthesis in the macrophage nucleus, were made during late G1 
as well as S. 
Melanoma  cells  and  macrophages  differ  in  their  radiolabeled  acid-soluble 
products after incubation in thymidine-3H. Thymidine taken up by the macro- 
phage remained unphosphorylated, whereas it was recovered mainly as thymi- 
dine triphosphate from melanoma cells. 
These  findings,  as  well  as  those  reported  previously,  suggest  that  the 
melanoma  cell  provides  the  RNA,  protein,  and  precursors  which  initiate 
macrophage DNA synthesis. In the absence of a  requirement for new macro- 
phage RNA and protein synthesis,  other changes must be responsible for the 
2 hr delay in DNA synthesis.  These may involve physical changes in  DNA, 
associated with  swelling,  as well as the transport  of melanoma products into 
the macrophage nucleus. 
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